Amylyx Pharmaceuticals, Inc. AMLX EBITDA

EBITDA at other companies

MBX Biosciences, Inc.MBX

-$27.2M-2.8%

Crinetics PharmaceuticalsCRNX

-$139.22M-26.0%

VAN

Vivani MedicalVANI

-$6.69M-3.6%

uniQureQURE

-$47.3M-17.5%

MeiraGTx Holdings plcMGTX

-$37.81M+1.8%

AdaptHealthAHCO

$111.96M-4.7%

FAQ

What is Amylyx Pharmaceuticals, Inc.'s EBITDA?

Amylyx Pharmaceuticals, Inc. (AMLX) reported EBITDA of -$45.65M in Q2 2026.

How has Amylyx Pharmaceuticals, Inc.'s EBITDA changed year-over-year?

Amylyx Pharmaceuticals, Inc.'s EBITDA decreased by 6.9% year-over-year, from -$42.72M to -$45.65M.

What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s EBITDA?

Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s EBITDA has grown at a 16.6% compound annual growth rate (CAGR), from -$82.64M to -$152.77M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.